[HLA 匹配的同胞供者异基因造血干细胞移植的血液系统恶性肿瘤中白细胞介素 -18 单核苷酸多态性]

[IL-18 single nucleotide polymorphisms in hematologic malignancies with HLA matched sibling donor allogeneic hematopoietic stem cell transplantation].

作者信息

Cai Xiaojin, Song Axia, Wang Hua, Zhang Ping, Zhang Guixin, Yang Fan, Wei Jialin, Ma Qiaoling, Yan Zhangsong, Jiang Erlie, Huang Yong, Yang Donglin, Wang Mei, He Yi, Han Mingzhe, Feng Sizhou

机构信息

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2014 Mar;35(3):215-20. doi: 10.3760/cma.j.issn.0253-2727.2014.03.008.

DOI:10.3760/cma.j.issn.0253-2727.2014.03.008

PMID:24666487

Abstract

OBJECTIVE

To explore the impact of interleukin-18 (IL-18) single nucleotide polymorphisms on outcomes of hematologic malignancies with HLA-matched sibling donor hematopoietic stem cell transplantation (allo-HSCT).

METHODS

Single- nucleotide polymorphisms in IL-18 promoter was detected by PCR-sequence-specific primer analysis (PCR-SSP) in 93 recipients and their HLA matched sibling donors. Hematopoietic reconstitution, incidences of graft versus host disease (GVHD) and infections, transplant related mortality (TRM), and disease free survival (DFS) were analyzed.

RESULTS

In comparison with -137 G/C+C/C donor genotype, patients with -137 G/G donor genotype had shorter duration of neutrophil recovery [15(11-23) days vs 17(11-24) days, P=0.01], higher incidence of extensive chronic GVHD (20.6% vs 3.3%, P=0.029), but no difference in the interval of platelet recovery [20(11-46) days vs 20(7-38) days, P=0.844]. The incidence of extensive chronic GVHD in -607 C/C donor genotype (31.6%) was significantly higher than that (10.8%) in C/A + A/A donor genotype (P=0.024). Recipients with -607 C/C genotype also had higher incidence (33.3%) of extensive chronic GVHD than those with C/A+A/A genotype (10.7%, P=0.016). There were no differences in acute GVHD, TRM, and DFS between different genotypes.

CONCLUSION

IL-18 -137 G homozygous genotype in donor facilitated neutrophil reconstitution, but increased the risk of extensive chronic GVHD in patients with allo-HSCT.

摘要

目的

探讨白细胞介素-18（IL-18）单核苷酸多态性对 HLA 配型相合的同胞供者造血干细胞移植（allo-HSCT）治疗血液系统恶性肿瘤疗效的影响。

方法

采用聚合酶链反应-序列特异性引物分析（PCR-SSP）技术检测 93 例接受 allo-HSCT 的患者及其 HLA 配型相合的同胞供者 IL-18 启动子区的单核苷酸多态性。分析造血重建、移植物抗宿主病（GVHD）和感染发生率、移植相关死亡率（TRM）及无病生存率（DFS）。

结果

与-137G/C+C/C 供者基因型相比，-137G/G 供者基因型患者中性粒细胞恢复时间较短[15（11-23）天对 17（11-24）天，P=0.01]，广泛慢性 GVHD 发生率较高（20.6%对 3.3%，P=0.029），但血小板恢复时间差异无统计学意义[20（11-46）天对二十（7-38）天，P=0.844]。-607C/C 供者基因型患者广泛慢性 GVHD 发生率（31.6%）显著高于 C/A+A/A 供者基因型患者（10.8%，P=0.024）。-607C/C 基因型受者广泛慢性 GVHD 发生率（33.3%）也高于 C/A+A/A 基因型受者（10.7%，P=0.016）。不同基因型在急性 GVHD、TRM 和 DFS 方面差异无统计学意义。